449 related articles for article (PubMed ID: 27416327)
1. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation.
Introna M; Lussana F; Algarotti A; Gotti E; Valgardsdottir R; Micò C; Grassi A; Pavoni C; Ferrari ML; Delaini F; Todisco E; Cavattoni I; Deola S; Biagi E; Balduzzi A; Rovelli A; Parma M; Napolitano S; Sgroi G; Marrocco E; Perseghin P; Belotti D; Cabiati B; Gaipa G; Golay J; Biondi A; Rambaldi A
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2070-2078. PubMed ID: 28712935
[TBL] [Abstract][Full Text] [Related]
3. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
4. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
Merker M; Salzmann-Manrique E; Katzki V; Huenecke S; Bremm M; Bakhtiar S; Willasch A; Jarisch A; Soerensen J; Schulz A; Meisel R; Bug G; Bonig H; Klingebiel T; Bader P; Rettinger E
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1281-1292. PubMed ID: 30878607
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.
Introna M; Borleri G; Conti E; Franceschetti M; Barbui AM; Broady R; Dander E; Gaipa G; D'Amico G; Biagi E; Parma M; Pogliani EM; Spinelli O; Baronciani D; Grassi A; Golay J; Barbui T; Biondi A; Rambaldi A
Haematologica; 2007 Jul; 92(7):952-9. PubMed ID: 17606446
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
[TBL] [Abstract][Full Text] [Related]
10. Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.
Narayan R; Benjamin JE; Shah O; Tian L; Tate K; Armstrong R; Xie BJ; Lowsky R; Laport G; Negrin RS; Meyer EH
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1293-1303. PubMed ID: 30951840
[TBL] [Abstract][Full Text] [Related]
11. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy.
Ballen KK; Becker PS; Emmons RV; Fitzgerald TJ; Hsieh CC; Liu Q; Heyes C; Clark Y; Levy W; Lambert JF; Chiafari F; Szymanski I; Rososhansky S; Popovsky MA; Stewart FM; Quesenberry PJ
Blood; 2002 Jul; 100(2):442-50. PubMed ID: 12091334
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
14. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124
[TBL] [Abstract][Full Text] [Related]
15. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934
[TBL] [Abstract][Full Text] [Related]
16. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies.
Linn YC; Niam M; Chu S; Choong A; Yong HX; Heng KK; Hwang W; Loh Y; Goh YT; Suck G; Chan M; Koh M
Bone Marrow Transplant; 2012 Jul; 47(7):957-66. PubMed ID: 21986635
[TBL] [Abstract][Full Text] [Related]
17. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
19. Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
Picardi A; Fabritiis Pd Pd; Cudillo L; Dentamaro T; Cupelli L; Ballatore G; Venditti A; Caravita T; Cristina Cox M; Catalano G; Amadori S
Hematol J; 2004; 5(1):24-31. PubMed ID: 14745426
[TBL] [Abstract][Full Text] [Related]
20. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Petersen EJ; Lokhorst HL; Verdonck LF
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]